GlassScriptPhysician profile
Andrea J Eisenberg
NPI 1174507156
$3,848.10
in general payments reported to CMS, 2019-2025
37 companies · $428 in 2025
The $428 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $194 · 2021: $564 · 2022: $988 · 2023: $658 · 2024: $500 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.07 | 2019-2024 | |
| Myovant Sciences INC. | $307.73 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $299.51 | 2021-2025 | |
| Pfizer INC. | $253.30 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $231.45 | 2023-2024 | Myfembree |
| Astellas Pharma US INC | $211.69 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $201.65 | 2019-2025 | Injectafer |
| Aspira Women'S Health INC | $166.92 | 2022 | |
| Amgen INC. | $133.22 | 2019-2024 | Evenity, Prolia |
| Coopersurgical, INC. | $126.51 | 2021-2025 | Paragard T 380a, Endosee |
| Exeltis, USA INC. | $113.91 | 2019-2025 | Slynd |
| Astrazeneca Pharmaceuticals LP | $111.79 | 2019 | |
| Hologic Sales and Service, LLC | $106.34 | 2019-2023 | Acessa Provu System |
| Therapeuticsmd, INC. | $105.45 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $70.37 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.07 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $61.17 | 2021-2022 | |
| Shield Therapeutics INC | $60.15 | 2023-2025 | Accrufer |
| Organon LLC | $58.39 | 2021-2022 | |
| Sage Therapeutics, LLC | $55.04 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $53.08 | 2021-2022 | |
| Scynexis, INC. | $45.07 | 2022 | |
| Evofem Biosciences, INC. | $43.67 | 2020-2022 | |
| Millicent US INC | $37.79 | 2025 | Femlyv, Femring, Intrarosa |
| Gynesonics, INC. | $35.70 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Avion Pharmaceuticals | $27.29 | 2019-2023 | Balcoltra |
| Ascend Therapeutics US, LLC | $26.48 | 2022 | |
| Meditrina | $24.76 | 2023-2024 | |
| Medicem INC. | $18.01 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.78 | 2019 | |
| Minerva Surgical, INC | $14.67 | 2023 | |
| Seqirus USA INC | $13.97 | 2022 | |
| Merck Sharp & Dohme LLC | $12.58 | 2020 | |
| Becton, Dickinson and Company | $12.37 | 2021 | |
| Duchesnay USA Incorporated | $11.22 | 2019 | |
| Lupin INC. | $10.93 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Eisenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.